Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

BACKGROUND: Sorafenib remains one major first-line therapeutic options for advanced hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of gemcitabine and oxaliplatin (GEMOX) to sorafenib in aHCC patients. METHODS: Our multicentre phase II trial randomised aHCC first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Assenat, Eric, Pageaux, Georges-Philippe, Thézenas, Simon, Peron, Jean-Marie, Bécouarn, Yves, Seitz, Jean-François, Merle, Philippe, Blanc, Jean-Frédéric, Bouché, Olivier, Ramdani, Mohamed, Poujol, Sylvain, de Forges, Hélène, Ychou, Marc, Boige, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734663/
https://www.ncbi.nlm.nih.gov/pubmed/30944458
http://dx.doi.org/10.1038/s41416-019-0443-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734663/
https://www.ncbi.nlm.nih.gov/pubmed/30944458
http://dx.doi.org/10.1038/s41416-019-0443-4

Ejemplares similares